Download PDF
CC BY-NC-ND 4.0 · AJP Rep 2020; 10(03): e234-e240
DOI: 10.1055/s-0040-1713785
Case Report

Use of Placental Growth Factor for Trisomy 21 Screening in Pregnancy: A Systematic Review

Ahmad Badeghiesh
1   Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
,
Alexander Volodarsky-Perel
1   Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
2   Lady Davis Research Institute, Jewish General Hospital, Montreal, Quebec, Canada
,
Ariane Lasry
1   Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
,
Robert Hemmings
1   Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
3   Department of Obstetrics and Gynecology, CIUSS Ouest de l'Ile, Montreal, Quebec, Canada
,
Yaron Gil
1   Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
,
Jacques Balayla
1   Department of Obstetrics and Gynecology, McGill University, Montreal, Quebec, Canada
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background Prenatal serum screening is an important modality to screen for aneuploidy in pregnancy. The addition of placental growth factor (PLGF) to screen for trisomy 21 remains controversial.

Objective To determine whether the addition of PLGF to combined serum aneuploidy screening improves detection rates (DRs) for trisomy 21.

Study Design We performed a systematic review of the literature until October 2019 to determine the benefits of adding PLGF to prenatal screening. We performed a goodness-of-fit test and retrieved the coefficient of determinations (R 2) as a function of false positive rates (FPRs), providing mean-weighted improvements in the DRs after accounting for PLGF levels.

Results We identified 51 studies, of which 8 met inclusion criteria (834 aneuploidy cases and 105,904 euploid controls). DRs were proportional to FPR across all studies, ranging from 59.0 to 95.3% without PLGF and 61.0 to 96.3% with PLGF (FPR 1–5%). Goodness-of-fit regression analysis revealed a logarithmic distribution of DRs as a function of the FPR, with R 2 = 0.109 (no PLGF) and R 2 = 0.06 (PLGF). Two-sample Kolmogorov–Smirnov's test reveals a p-value of 0.44. Overall, addition of PLGF improves DRs of 3.3% for 1% FPR, 1.7% for 3% FPR, and 1.4% for 5% FPR, respectively.

Conclusion Addition of PLGF to prenatal screening using serum analytes mildly improves trisomy 21 DRs as a function of FPRs.

Keywords

PLGF - placental growth factor - trisomy 21 - prenatal screening - aneuploidy


Publication History

Received: 05 January 2020

Accepted: 05 March 2020

Article published online:
27 August 2020

© 2020. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 

  • References

  • 1 Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature 2005; 438 (7070): 937-945
    CrossrefPubMedGoogle Scholar
  • 2 Schlembach D, Wallner W, Sengenberger R. , et al. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction. Ultrasound Obstet Gynecol 2007; 29 (04) 407-413
    CrossrefPubMedGoogle Scholar
  • 3 Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31 (05) 493-502
    CrossrefPubMedGoogle Scholar
  • 4 Pollheimer J, Knöfler M. Signalling pathways regulating the invasive differentiation of human trophoblasts: a review. Placenta 2005; 26 (Suppl A): S21-S30
    CrossrefPubMedGoogle Scholar
  • 5 Chitayat D, Langlois S, Douglas Wilson R. ,; SOGC GENETICS COMMITTEE; CCMG PRENATAL DIAGNOSIS COMMITTEE. Prenatal screening for fetal aneuploidy in singleton pregnancies. J Obstet Gynaecol Can 2011; 33 (07) 736-750
    CrossrefPubMedGoogle Scholar
  • 6 Huang T, Dennis A, Meschino WS, Rashid S, Mak-Tam E, Cuckle H. First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy-associated plasma protein A, free-β human chorionic gonadotrophin, placental growth factor, and α-fetoprotein. Prenat Diagn 2015; 35 (07) 709-716
    CrossrefPubMedGoogle Scholar
  • 7 Wright D, Syngelaki A, Bradbury I, Akolekar R, Nicolaides KH. First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Fetal Diagn Ther 2014; 35 (02) 118-126
    CrossrefPubMedGoogle Scholar
  • 8 Wheeler DM, Sinosich MJ. Prenatal screening in the first trimester of pregnancy. Prenat Diagn 1998; 18 (06) 537-543
    CrossrefPubMedGoogle Scholar
  • 9 Khalil A, Muttukrishna S, Harrington K, Jauniaux E. Effect of antihypertensive therapy with alpha methyldopa on levels of angiogenic factors in pregnancies with hypertensive disorders. PLoS One 2008; 3 (07) e2766
    CrossrefPubMedGoogle Scholar
  • 10 Shore VH, Wang TH, Wang CL, Torry RJ, Caudle MR, Torry DS. Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 1997; 18 (08) 657-665
    CrossrefPubMedGoogle Scholar
  • 11 Saffer C, Olson G, Boggess KA, Beyerlein R, Eubank C, Sibai BM. ; NORMALS Study Group. Determination of placental growth factor (PlGF) levels in healthy pregnant women without signs or symptoms of preeclampsia. Pregnancy Hypertens 2013; 3 (02) 124-132
    CrossrefPubMedGoogle Scholar
  • 12 Lai J, Garcia-Tizon Larroca S, Peeva G, Poon LC, Wright D, Nicolaides KH. Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation. Fetal Diagn Ther 2014; 35 (04) 240-248
    CrossrefPubMedGoogle Scholar
  • 13 Levine RJ, Maynard SE, Qian C. , et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350 (07) 672-683
    CrossrefPubMedGoogle Scholar
  • 14 Chau K, Hennessy A, Makris A. Placental growth factor and pre-eclampsia. J Hum Hypertens 2017; 31 (12) 782-786
    CrossrefPubMedGoogle Scholar
  • 15 Poon LC, Zaragoza E, Akolekar R, Anagnostopoulos E, Nicolaides KH. Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation. Prenat Diagn 2008; 28 (12) 1110-1115
    CrossrefPubMedGoogle Scholar
  • 16 Bujold E, Roberge S, Lacasse Y. , et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010; 116 (2 Pt 1): 402-414
    CrossrefPubMedGoogle Scholar
  • 17 Rolnik DL, Wright D, Poon LC. , et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377 (07) 613-622
    CrossrefPubMedGoogle Scholar
  • 18 Kagan KO, Hoopmann M, Abele H, Alkier R, Lüthgens K. First-trimester combined screening for trisomy 21 with different combinations of placental growth factor, free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2012; 40 (05) 530-535
    CrossrefPubMedGoogle Scholar
  • 19 Cowans NJ, Stamatopoulou A, Tørring N, Spencer K. Early first-trimester maternal serum placental growth factor in trisomy 21 pregnancies. Ultrasound Obstet Gynecol 2011; 37 (05) 515-519
    CrossrefPubMedGoogle Scholar
  • 20 Spencer K, Liao AW, Ong CY, Geerts L, Nicolaides KH. First trimester maternal serum placenta growth factor (PIGF)concentrations in pregnancies with fetal trisomy 21 or trisomy 18. Prenat Diagn 2001; 21 (09) 718-722
    CrossrefPubMedGoogle Scholar
  • 21 Cowans NJ, Stamatopoulou A, Spencer K. First trimester maternal serum placental growth factor in trisomy 21 pregnancies. Prenat Diagn 2010; 30 (05) 449-453
    CrossrefPubMedGoogle Scholar
  • 22 Zaragoza E, Akolekar R, Poon LC, Pepes S, Nicolaides KH. Maternal serum placental growth factor at 11-13 weeks in chromosomally abnormal pregnancies. Ultrasound Obstet Gynecol 2009; 33 (04) 382-386
    CrossrefPubMedGoogle Scholar
  • 23 Su YN, Hsu JJ, Lee CN, Cheng WF, Kung CC, Hsieh FJ. Raised maternal serum placenta growth factor concentration during the second trimester is associated with Down syndrome. Prenat Diagn 2002; 22 (01) 8-12
    CrossrefPubMedGoogle Scholar
  • 24 Debieve F, Moiset A, Thomas K, Pampfer S, Hubinont C. Vascular endothelial growth factor and placenta growth factor concentrations in Down's syndrome and control pregnancies. Mol Hum Reprod 2001; 7 (08) 765-770
    CrossrefPubMedGoogle Scholar
  • 25 Cowans NJ, Kisanga MC, Spencer K. Maternal serum placental growth factor in second trimester trisomy 21 pregnancies. Prenat Diagn 2012; 32 (02) 117-121
    CrossrefPubMedGoogle Scholar
  • 26 Lambert-Messerlian GM, Canick JA. Placenta growth factor levels in second-trimester maternal serum in Down syndrome pregnancy and in the prediction of preeclampsia. Prenat Diagn 2004; 24 (11) 876-880
    CrossrefPubMedGoogle Scholar
  • 27 Cowans NJ, Kisanga M, Khan A, Spencer K. A comparison of two immunoassay methods for the measurement of maternal serum placental growth factor in early pregnancy. Fetal Diagn Ther 2012; 31 (04) 254-259
    CrossrefPubMedGoogle Scholar
  • 28 Han J, Liu H, Xu ZP. , et al. Maternal serum PlGF (placental growth factor) in Chinese women in the first trimester undergoing screening for Down syndrome. Eur J Obstet Gynecol Reprod Biol 2016; 201: 166-170
    CrossrefPubMedGoogle Scholar
  • 29 Koster MP, Wortelboer EJ, Stoutenbeek P, Visser GH, Schielen PC. Modeling Down syndrome screening performance using first-trimester serum markers. Ultrasound Obstet Gynecol 2011; 38 (02) 134-139
    CrossrefPubMedGoogle Scholar
  • 30 Benn P, Borell A, Chiu R. , et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenat Diagn 2013; 33 (07) 622-629
    CrossrefPubMedGoogle Scholar
  • 31 Boulet SL, Molinari NA, Grosse SD, Honein MA, Correa-Villaseñor A. Health care expenditures for infants and young children with Down syndrome in a privately insured population. J Pediatr 2008; 153 (02) 241-246
    CrossrefPubMedGoogle Scholar
  • 32 Pandya P, Wright D, Syngelaki A, Akolekar R, Nicolaides KH. Maternal serum placental growth factor in prospective screening for aneuploidies at 8-13 weeks' gestation. Fetal Diagn Ther 2012; 31 (02) 87-93
    CrossrefPubMedGoogle Scholar
  • 33 Boutin A, Demers S, Gasse C. , et al. First trimester screening for fetal aneuploidies using placental growth factor: the Great Obstetrical Syndrome (GOS) study. J Obstet Gynaecol Can 2018; 40 (08) 1044-1049
    CrossrefPubMedGoogle Scholar